Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.92 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.92 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.92 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.92 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.92 |
| ▸ | DRD1 | P21728 | 3/20 | 0.92 |
| ▸ | DRD3 | P35462 | 3/20 | 0.92 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.92 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.92 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.92 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.92 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.92 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.92 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.92 |
| ▸ | HTR2A | P28223 | 1/20 | 0.92 |
| ▸ | HTR2C | P28335 | 1/20 | 0.92 |
| ▸ | HTR2B | P41595 | 1/20 | 0.92 |
| ▸ | HTR1A | P08908 | 2/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclizine SCHEMBL4690 | 0.96 | CYP2D6 (1.00) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Cyclizine SCHEMBL19514707 | 0.94 | CYP2D6 (0.96) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Cyclizine SCHEMBL97825 | 0.94 | CYP2D6 (0.96) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL12359491 | 0.89 | CHRM1 (0.79) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Cyclizine SCHEMBL5656056 | 0.87 | CYP2D6 (0.82) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL2615164 | 0.85 | CYP2D6 (0.79) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Chlorcyclizine SCHEMBL13724147 | 0.85 | KCNH2 (1.00) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL2615162 | 0.85 | CYP2D6 (0.79) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Chlorcyclizine SCHEMBL4383 | 0.85 | KCNH2 (1.00) | CYP2D6CHRM2ADRA2ACHRM1DRD1 | |
| Chlorcyclizine SCHEMBL12157065 | 0.85 | KCNH2 (1.00) | CYP2D6CHRM2ADRA2ACHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1876 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| EP-2956119-B1 | NANOPARTICLE DELIVERY COMPOSITIONS | MIDATECH LTD (GB) | 2019-08-14 | — | — | EP | claimed |
| US-10300022-B2 | Nanoparticle delivery compositions | MIDATECH LTD. (GB) | 2019-05-28 | — | — | US | claimed |
| WO-2018002696-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AN ANTIHISTAMINE AGENT | FLEMING LABORATORIES LIMITED (IN) | 2018-01-04 | — | — | WO | claimed |
| US-20160338972-A1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC. | 2016-11-24 | — | — | US | claimed |
| US-20160151299-A1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC. | 2016-06-02 | — | — | US | claimed |
| EP-2956119-A1 | NANOPARTICLE DELIVERY COMPOSITIONS | Midatech Ltd. (GB) | 2015-12-23 | — | — | EP | claimed |
| CN-105073097-A | Nanoparticle delivery compositions | MIDATECH LTD | 2015-11-18 | — | — | CN | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1993024154-A1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | FUISZ TECHNOLOGIES, LTD. (US) | 1993-12-09 | — | — | WO | claimed |
| EP-0486563-B1 | CHEWING GUM COMPOSITION WITH ACCELERATED, CONTROLLED RELEASE OF ACTIVE AGENTS | FERTIN A/S (DK) | 1993-09-08 | — | — | EP | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4654209-A | NITROGLYCERINE PLUS STEROID, ANTIHISTAMINE, ANALGESIC, ANTIMICROBIAL | EUROCELTIQUE, S.A. (LU) | 1987-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338972-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | HRH1 1049/4885CYP2D6 144/4885CHRM2 82/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | HRH1 1389/4885CYP2D6 3747/4885CHRM2 2857/4885 |
| US-20160151299-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | HRH1 1049/4885CYP2D6 144/4885CHRM2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.